Maria E. Cabanillas, MD

Articles

Dr Cabanillas on Delivering the "Right" Surgery to Patients With MTC

April 19th 2022

Maria E. Cabanillas, MD, an oncologic endocrinologist, tenured professor and the faculty director of clinical research in the department of Endocrine Neoplasia at The University of Texas MD Anderson Cancer Center, discusses how to deliver the optimal surgical approach to patients with medullary thyroid cancer.

Dr Cabanillas on Current Systemic Treatments in MTC and the Potential for PRRT

April 19th 2022

Maria E. Cabanillas, MD, oncologic endocrinologist, tenured professor and the faculty director of clinical research in the department of Endocrine Neoplasia at The University of Texas MD Anderson Cancer Center, discusses current systemic treatments in medullary thyroid cancer, along with the potential for peptide receptor radionuclide therapy.

Novel Treatment Advances in Differentiated Thyroid Cancer

February 3rd 2022

An overview of therapies in the pipeline for differentiated thyroid cancer and their potential effect on clinical decision-making.

BRAF Inhibitors and Immunotherapy for Differentiated Thyroid Cancer

February 3rd 2022

The role of BRAF inhibitors and checkpoint inhibitors in differentiated thyroid cancer, and potential considerations for using BRAF inhibition as redifferentiation therapy.

RET and NTRK Inhibitors for Differentiated Thyroid Cancer

January 28th 2022

The rationale for targeting actionable mutations in differentiated thyroid cancer with RET and NTRK inhibitors.

Systemic Therapy Algorithms in DTC

January 28th 2022

Considerations regarding approaches to sequencing therapies for differentiated thyroid cancer.

Targeted Treatments for Differentiated Thyroid Cancer

January 21st 2022

An overview of the types of targeted drug classes available to treat differentiated thyroid cancer at various clinical stages.

When to Initiate Therapy for Differentiated Thyroid Cancer

January 21st 2022

Maria E. Cabanillas, MD, describes what triggers her to initiate therapy for differentiated thyroid cancer and variables that impact treatment choice.

Dr. Cabanillas on Lenvatinib as First-Line Therapy for Patients With DTC

February 20th 2016

Maria E. Cabinillas, MD, associate professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses administering lenvatinib (Lenvima) as a first-line therapy for patients with differentiated thyroid cancer (DTC).